Expression patterns of CD28 and CTLA-4 in early, chronic, and untreated rheumatoid arthritis.
CD28
CTLA4
Rheumatoid arthritis
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
11
09
2019
revised:
09
12
2019
accepted:
10
12
2019
pubmed:
8
1
2020
medline:
21
5
2021
entrez:
8
1
2020
Statut:
ppublish
Résumé
T-cell activation pathways have been proposed as trigger mechanisms in the pathogenesis of rheumatoid arthritis (RA). CD28 and CTLA-4 play major roles in regulating the stimulatory and inhibitory co-signals in T cells. To analyze the association between soluble and surface expression of CD28 and CTLA-4 with the clinical parameters of RA patients. A total of 35 RA patients classified as early RA (n = 14), chronic RA (n = 14), and untreated RA (n = 7), as well as 7 age- and sex-matched control subjects (CS) were included. Surface expression of CD28 and CTLA-4 on T cells was evaluated by flow cytometry. Soluble levels of CD28 (sCD28), CTLA-4 (sCTLA-4), and anti-CCP antibodies were measured by ELISA. A significant lower percentage of CD8 + T cells positive to CD28 (CS = 64.9% vs RA = 42.7%, P = .04), and diminished surface expression of CD28 (CS: MFI = 122.9 vs RA: MFI = 33.1, P = .006), were found in chronic RA patients compared to CS. Higher sCD28 were observed in early RA patients compared with chronic RA patients (P < .05). sCTLA-4 was found increased in untreated RA patients compared to early RA patients (P < .05). sCD28 concentration correlated with anti-CCP levels (rho = -0.12; P = .032). The soluble and surface expressions of CTLA-4 were not associated with RA clinical parameters. In RA, the percentage of CD8 + CD28+ T cells decreases and expresses fewer membrane CD28 than CS. sCD28 levels are lower in chronic RA and are associated negatively with anti-CCP levels. sCTLA 4 levels are lower in early RA patients than in untreated RA patients.
Sections du résumé
BACKGROUND
BACKGROUND
T-cell activation pathways have been proposed as trigger mechanisms in the pathogenesis of rheumatoid arthritis (RA). CD28 and CTLA-4 play major roles in regulating the stimulatory and inhibitory co-signals in T cells.
OBJECTIVE
OBJECTIVE
To analyze the association between soluble and surface expression of CD28 and CTLA-4 with the clinical parameters of RA patients.
METHODS
METHODS
A total of 35 RA patients classified as early RA (n = 14), chronic RA (n = 14), and untreated RA (n = 7), as well as 7 age- and sex-matched control subjects (CS) were included. Surface expression of CD28 and CTLA-4 on T cells was evaluated by flow cytometry. Soluble levels of CD28 (sCD28), CTLA-4 (sCTLA-4), and anti-CCP antibodies were measured by ELISA.
RESULTS
RESULTS
A significant lower percentage of CD8 + T cells positive to CD28 (CS = 64.9% vs RA = 42.7%, P = .04), and diminished surface expression of CD28 (CS: MFI = 122.9 vs RA: MFI = 33.1, P = .006), were found in chronic RA patients compared to CS. Higher sCD28 were observed in early RA patients compared with chronic RA patients (P < .05). sCTLA-4 was found increased in untreated RA patients compared to early RA patients (P < .05). sCD28 concentration correlated with anti-CCP levels (rho = -0.12; P = .032). The soluble and surface expressions of CTLA-4 were not associated with RA clinical parameters.
CONCLUSIONS
CONCLUSIONS
In RA, the percentage of CD8 + CD28+ T cells decreases and expresses fewer membrane CD28 than CS. sCD28 levels are lower in chronic RA and are associated negatively with anti-CCP levels. sCTLA 4 levels are lower in early RA patients than in untreated RA patients.
Identifiants
pubmed: 31907973
doi: 10.1002/jcla.23188
pmc: PMC7246387
doi:
Substances chimiques
Anti-Citrullinated Protein Antibodies
0
Biomarkers
0
CD28 Antigens
0
CTLA-4 Antigen
0
CTLA4 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23188Subventions
Organisme : Consejo Nacional de Ciencia y Tecnología
ID : Grant A1-S-8774 (CONACYT Ciencia Básica
Informations de copyright
© 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc.
Références
Lupus. 2008 Jul;17(7):630-7
pubmed: 18625635
J Immunol. 2002 Aug 15;169(4):1984-92
pubmed: 12165524
Dis Markers. 2011;30(1):25-9
pubmed: 21508506
Toxins (Basel). 2018 Nov 06;10(11):
pubmed: 30404186
Biochem Biophys Res Commun. 1999 May 27;259(1):34-7
pubmed: 10334911
F1000Res. 2018 May 30;7:
pubmed: 29904580
Auto Immun Highlights. 2010 Nov 04;1(2):73-81
pubmed: 26000110
Clin Immunol. 2007 May;123(2):190-8
pubmed: 17321799
Biomed Res Int. 2014;2014:215763
pubmed: 24605322
Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19396-401
pubmed: 19036923
Ryumachi. 2001 Dec;41(6):929-37
pubmed: 11831013
Immunology. 2011 Sep;134(1):17-32
pubmed: 21711350
Scand J Immunol. 2014 Feb;79(2):149-55
pubmed: 24313359
Am J Transplant. 2014 Feb;14(2):305-18
pubmed: 24410845
Front Immunol. 2018 Aug 27;9:1941
pubmed: 30210496
J Immunol Res. 2018 Aug 5;2018:3758713
pubmed: 30155493
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
Cell Immunol. 2000 May 1;201(2):144-53
pubmed: 10831323
Arthritis Res Ther. 2009;11(4):R101
pubmed: 19570209
Immunol Lett. 2006 Apr 15;104(1-2):70-5
pubmed: 16413062
Scand J Rheumatol. 2002;31(5):251-9
pubmed: 12455813
Genet Test Mol Biomarkers. 2013 Apr;17(4):336-41
pubmed: 23448385
J Exp Med. 1994 Feb 1;179(2):609-18
pubmed: 8294871
Int Immunopharmacol. 2012 Dec;14(4):585-92
pubmed: 22917707
Nat Rev Dis Primers. 2018 Feb 08;4:18001
pubmed: 29417936
J Virol. 2001 Dec;75(24):12182-7
pubmed: 11711609
Arthritis Rheum. 2013 Jan;65(1):81-7
pubmed: 23045162
Arthritis Rheum. 2001 Jan;44(1):13-20
pubmed: 11212151
Nat Rev Immunol. 2001 Dec;1(3):220-8
pubmed: 11905831
Clin Exp Immunol. 2013 Oct;174(1):18-26
pubmed: 23786396
J Clin Lab Anal. 2020 May;34(5):e23188
pubmed: 31907973
Clin Exp Immunol. 1997 Mar;107(3):548-54
pubmed: 9067531
N Engl J Med. 2003 Nov 13;349(20):1907-15
pubmed: 14614165
Cell Mol Immunol. 2015 Nov;12(6):708-18
pubmed: 25482073
Immunol Rev. 2008 Jun;223:143-55
pubmed: 18613834
Arch Immunol Ther Exp (Warsz). 2005 Jul-Aug;53(4):336-41
pubmed: 16088318
Blood. 2003 Jan 1;101(1):202-9
pubmed: 12393538